Interaction of RNA Binding Proteins ID'd in Glioblastoma

This article originally appeared here.
Share this content:
Interaction of RNA Binding Proteins ID'd in Glioblastoma
Interaction of RNA Binding Proteins ID'd in Glioblastoma

(HealthDay News) – The RNA-binding protein (RBP) HuR interacts with and regulates Musashi1 (Msi1) post-transcriptionally in glioblastoma cells, according to an experimental study published in the January issue of Molecular Cancer Research.

Dat T. Vo, from the University of Texas Health Science Center at San Antonio, and colleagues investigated the interaction between HuR and Msi1 in glioblastoma cells. Quantitative real time polymerase chain reactions were used to measure HuR and Msi1 in clinical glioblastoma samples.

The researchers found that HuR interacted with the 3'-untranslated region of Msi1, positively regulating Msi1 expression. HuR increased mRNA stability and promoted translation of MSI1. Expression of HuR and Msi1 were positively associated in glioblastoma samples. Silencing of HuR resulted in inhibition of cell proliferation, increases in apoptosis, and changes in the cell-cycle profile, which were partially rescued by ectopic expression of Msi1.

"The HuR:Msi1 relationship discussed in this article creates a positive cascade network motif where the cellular logic for gliomagenesis requires HuR to essentially "activate" Msi1 gene expression," the authors write. "The interaction between these two RBPs creates a two-component composite gene regulatory network."

Abstract
Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs